ALVAL Stock Overview
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Valbiotis SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.90 |
| 52 Week High | €7.50 |
| 52 Week Low | €2.90 |
| Beta | -0.30 |
| 1 Month Change | 7.44% |
| 3 Month Change | -7.80% |
| 1 Year Change | 30.00% |
| 3 Year Change | -47.79% |
| 5 Year Change | -3.47% |
| Change since IPO | -61.00% |
Recent News & Updates
Shareholder Returns
| ALVAL | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0.9% | 0.009% | 0.7% |
| 1Y | 30.0% | -5.2% | 3.4% |
Return vs Industry: ALVAL exceeded the French Biotechs industry which returned -5.2% over the past year.
Return vs Market: ALVAL exceeded the French Market which returned 3.5% over the past year.
Price Volatility
| ALVAL volatility | |
|---|---|
| ALVAL Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALVAL has not had significant price volatility in the past 3 months.
Volatility Over Time: ALVAL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 48 | Sebastien Peltier | www.valbiotis.com |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD.
Valbiotis SA Fundamentals Summary
| ALVAL fundamental statistics | |
|---|---|
| Market cap | €61.51m |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €6.81m |
9.0x
P/S Ratio-8.3x
P/E RatioIs ALVAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALVAL income statement (TTM) | |
|---|---|
| Revenue | €6.81m |
| Cost of Revenue | €2.04m |
| Gross Profit | €4.77m |
| Other Expenses | €12.13m |
| Earnings | -€7.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 69.98% |
| Net Profit Margin | -108.21% |
| Debt/Equity Ratio | 43.8% |
How did ALVAL perform over the long term?
See historical performance and comparison